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Abstract 
An elevated preprocedural plasma or serum C-reactive protein (CRP) level in patients undergoing 
percutanous coronary intervention (PCI) is associated with short-, intermediate- and long-term 
outcome. Furthermore, the procedure itself has been shown to provoke an inflammatory reaction as 
shown by increased plasma CRP levels after PCI. The research programme resulting in this thesis 
focus on the role of CRP and inflammation in patients undergoing PCI. 
In study I 400 consecutive patients with serum levels of troponin T ≤ 0.03 μg/l presenting with stable 
or unstable angina pectoris were investigated. Twenty-one percent of the patients experienced a 
myocardial infarction during PCI. The median value of CRP before the procedure was 1.83 (0.12-
99.7) mg/l. No difference was seen in CRP levels before PCI between patients without or with 
myocardial infarction during PCI. Multivariate analysis identified stent implantation, procedure time 
and complications during the procedure as independent predictors of myocardial infarction during 
PCI. 
In study II 121 patients with stable angina pectoris were enrolled. 100 patients were treated with a 
thrombin-based (Duett sealing) femoral artery closure device and 121 patients were treated with the 
FemoStop device. Irrespective of femoral artery closure device serum CRP and serum amyloid A 
(SAA) levels increased significantly after PCI. The increase was more pronounced in the Duett sealing 
device group compared with the FemoStop device group. 
In study III 100 patients with stable angina pectoris scheduled for elective PCI were prospectively 
enrolled. Antibodies against different pathogens were examined. Plasma CRP and IL-6 levels were 
measured before and 6, 24, 48, 72 hours after PCI. Neither infection with single or multiple pathogens 
nor a minor troponin T elevation after PCI was associated with plasma CRP or interleukin-6 (IL-6) 
area under the curves (AUCs). Patients treated with stent implantation had higher plasma CRP and IL-
6 AUCs compared with patients treated with balloon angioplasty alone  
Study 1V 891 consecutive patients presenting with stable or unstable angina pectoris undergoing a 
variety of PCIs were investigated. Serum concentrations of CRP and troponin T were determined 
before and the day after PCI. The mean follow-up time after PCI was 2.6 years. In multivariate 
analysis, patients in the highest tertile of CRP, induced by PCI, had an increased risk (risk ratio (RR) 
2.48 [95% confidence interval (CI) 1.42-4.33]) for death or non-fatal myocardial infarction. 
Furthermore, patients in the second (RR 1.75 [95% CI 1.14-2.75]) and third (RR 2.15 [95% CI 1.37-
3.36]) tertiles of the CRP response had an increased risk for coronary revascularization. Patients with 
periprocedural myocardial infarction with a postprocedural troponin T > 0.14 μg/l had an increased 
risk for death or non-fatal myocardial infarction (RR 2.65 [95% CI 1.02-6.83]). 
Conclusion: Periprocedural factors, whereas not the preprocedural CRP were associated with the risk 
of myocardial infarction during PCI. However, an elevated serum CRP concentration in response to 
PCI is a strong independent predictor of death or non-fatal myocardial infarction and coronary 
revascularization independent on myocardial injury during the procedure. Factors related to the 
procedure are influenced the CRP response to PCI. The results emphasize the role of CRP in coronary 
artery disease (CAD), and the need to develop treatments that block the increase in CRP in CAD. 
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ABBREVIATIONS 
ACC The American College of Cardiology 
AHA The American Heart Association 
ASA Acetyl salicylic acid 
AUC Area under the curve 
BMI Body mass index 
CABG Coronary artery bypass grafting 
CAD Coronary artery disease 
CK Creatine kinase 
CKMB Creatine kinase-MB 
CMV Cytomegalovirus 
CPN Chlamydia pneumoniae 
CRP C-reactive protein 
DCA Directional atherectomy 
EBV Epstein-Barr virus 
ECG Electrocardiogram  
eNOS Endothelial nitric oxide synthase 
ESC The European Soceity of Cardiology 
HDL High density lipoprotein 
HPY Helicobacter pylori  
HSV Herpes simplex virus  
ICAM-1 Interceullar cell adhesion molcule-1 
Ig Immunoglobulin  
IL Interleukin 
LDL  Low density lipoprotein  
MACE Major advanced cardiac events 
MCP Monocyte chemoattractant protein 
MCSF Macrophage colony-stimulating factor 
NO Nitric oxide   
PAI-1 Plasminogen activator inhibitor-1 
PCI Percutaneous coronary intervention 
PTCA  Percutaneous transluminal coronary angioplasty 
SAA Serum amyloid A 
SAP Serum amyloid P 
SMC Smooth muscle cell 
sPLA2 Secretory type II phospholipase A2 
SVG Saphenous vein graft 
TNF Tumor necrosis factor 
tPA Tissue plasminogen activator 
TVR Target vessel revascularization 
VCAM-1 Vascular cell adhesion molecule-1 
VLDL Very low density lipoprotein   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Despite a major decline in death rates from myocardial infarction, coronary artery disease (CAD) still 
remains the leading cause of morbidity and mortality in the Western world (Chockalingam 1999). 
Much of the decline in CAD related mortality is a result of better understanding of the 
pathophysiology of atherosclerosis and advent of new therapies. Furthermore, several new risk factors, 
which contribute to the pathogenesis of CAD, have been identified. Recently, emphasis has been 
placed on the presence of inflammation and infection in atherosclerosis as potential pathogenic factors.  
Atherosclerosis is a chronic disease that progress over decades (Fuster 1992). Atherogenesis 
represents a series of highly specific cellular and molecular responses to vascular injury and lipid 
infiltration into the intima and that can be described as an inflammatory process (Ross 1999). The two 
major theories of atherogenesis; i.e., oxidation of lipids and response to injury, may well be 
interrelated. 
A number of circulating indicators of vascular inflammation has been proposed such as acute phase 
reactants (C-reactive protein, fibrinogen and serum amyloid A), cytokines, leukocyte count and 
soluble adhesion molecules (Ridker 1999, Pearson 2003). The clinical utility of these markers depend 
on the ability to measure levels in plasma or serum accurately and reliably, and on their predictive 
value as demonstrated in clinical studies. 
Laboratory and clinical evidence favours CRP as the marker of preference for clinical application 
(Pearson 2003, Yeh 2003). It is the only analyte with acceptable laboratory standards considering 
assay availability, stability, World Health Organization standardization and precision. Furthermore, it 
has the largest database to support its clinical utility for assessing cardiovascular risk (Ridker 2003). 
Percutaneous coronary intervention (PCI) is an established coronary revascularization procedure. In 
the 27 years since the introduction of PCI, there has been an enormous increase in the volume of cases, 
number of operators and sites performing coronary angioplasty. Although the introduction of stents 
and adjunctive antithrombotic therapy has substantially reduced complications, including restenosis, a 
significant proportion of successfully treated patients experience early and late nonfatal or fatal 
ischemic events. The pathophysiologic mechanisms for these events include periprocedural 
myocardial infarction, in-stent restenosis or CAD progression in lesions that have not been subjected 
to intervention. The identification of these high-risk patients is essential in everyday clinical practice 
and remains a challenge. To more accurately risk stratify these patients, several clinical and 
angiographic characteristics as well as biochemical markers have been suggested. A previous study 
has shown that activation of inflammatory cells before PCI may play a role in the modulation of vessel 
wall response to the injury induced by balloon dilatation (Pietersma 1993). This possibility is 
supported by experimental and clinical studies showing that acute phase reactants and 
proinflammatory cytokines promote leukocyte, endothelial and smooth muscle cell activation, 
resulting in an increase in procoagulant activity, metalloproteinase release and neointimal proliferation 
(Cermak 1993, Galis 1995, Ikeda 1991).  
The research programme resulting in this thesis focus on the role of CRP and inflammation in patients 
undergoing PCI. 
Background 
Inflammation and atherosclerosis 
Atherosclerotic lesions occurs principally in large and
 
medium-sized elastic and muscular arteries and 
can result in ischemia
 
of the heart, brain or extremities, resulting in infarction.
 
Lesions of a varying 
degree might develop throughout an individuals lifetime. The pathogenesis of atherosclerosis is 
multifactorial and is influenced by hypercholesterolemia, hypertension, diabetes mellitus, smoking, 
and many other, as yet unidentified risk factors. Hypercholesterolemia plays a dominant role in the 
initiation and progression of the fatty streak, the earliest atherosclerotic lesion. Indeed, 
hypercholesterolemia induces fatty streaks in humans as early as during fetal development and seems 
to be essential for lesion development in animal models (Witztum 1999). 
The endothelium is an active, dynamic tissue that controls many important functions, including 
maintenance of blood circulation and fluidity as well as regulation of vascular tone, coagulation, and 
inflammatory responses (Gonzalez 2003). The arterial endothelium responds to flow and shear forces 
via a pathway that leads to phosphorylation of endothelial nitric oxide synthase (eNOS), that results in 
nitric oxide (NO) production (Gonzalez 2003). NO is one of the most important substances in 
preserving a normal vascular function. NO inhibits expression of adhesion molecules and cytokines 
(peng 1998). NO also possesses antithrombotic properties through its antiplatelet properties and 
inhibition of expression of tissue factor (Oeckler 2000). Furthermore, NO inhibits migration and 
proliferation of endothelial and smooth muscle cells (SMC), and diminished eNOS gene expression in 
atherosclerosis leads to increased proliferation and remodeling of the vessel wall (Oeckler 2000). 
The presence of CAD risk factors and/or atherosclerosis will result in impairment of the response of 
endothelium to flow and shear forces (Gonzalez 2003).  Possible causes of endothelial dysfunction 
include elevated low density lipoprotein (LDL), cigarette smoking, hypertension, diabetes mellitus, 
genetic alterations, elevated plasma homocysteine concentrations, hypertriglyceridemia and infection. 
Loss of the endothelium-dependent anticoagulant defence results in a procoagulant state with 
increased platelet aggregation, shortened platelet survival time, decreased tissue plasminogen activator 
(tPA), and increased plasminogen activator inhibitor-1 (PAI-1) secretion. Furthermore, impaired 
endothelial function is characterized by expression of leukocyte adhesion molecules, such as vascular 
cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1), and P-selectin 
(Price 1999). 
Once adherent to the endothelium leukocytes penetrate into
 
the intima. Recent research has identified 
candidate
 
chemoattractant molecules responsible for this transmigration.
 
Monocyte chemoattractant 
protein-1 (MCP-1) appears
 
responsible for the direct migration of monocytes into the intima
 
at sites of 
lesion formation (Gu 1998, Bohring 1998) whereas a family of T-cell chemoattractants
 
may likewise 
stimulate lymphocyte migration into the intima (Match 1999). Transendothelial migration of 
monocytes is followed by transformation to macrophages. These macrophages express scavenger 
receptors that binds and take up modified lipoproteins,
 
permitting macrophages to ingest lipid and 
become foam cells. Macrophage colony-stimulating factor (MCSF) contributes
 
to differentiation of 
blood borne monocytes to macrophages (Smith 1995, Qiao 1997). T cells likewise encounter signals 
that cause
 
them to elaborate inflammatory cytokines such as γ-interferon and tumor necrosis factor 
[TNF]–ß that in turn can stimulate macrophages as well as vascular endothelial and smooth muscle 
cells (Hansson 1996). As this inflammatory process continues, activated white blood cells secrete 
cytokines and growth factors that promote migration and proliferation of SMCs. SMCs located in the 
media express metalloproteinases that can degrade elastin and collagen in response to inflammatory 
stimulation. This degradation of the arterial extracellular matrix permits migration of SMCs through 
the elastic laminae and collagenous matrix of the growing plaque (Ross 1999). 
The inflammatory process do not only promote initiation and evolution
 
of atheroma, but do also 
contribute to precipitate
 
acute thrombotic complications of atheroma. About two thirds of
 
coronary 
arterial thrombi that cause fatal acute myocardial
 
infarction arise because of a physical disruption of 
the atherosclerotic
 
plaque. The activated macrophages, abundant in the atheroma, produces 
metalloproteinases capable of degrading collagen that lends
 strength to the plaque’s protective fibrous 
cap. Thus the cap become thin and weak, and susceptible to rupture. Furthermore, γ-Interferon arising 
from activated T lymphocytes in the plaque can halt
 
collagen synthesis by SMCs, limiting its capacity 
to renew the
 
collagen that reinforces the plaque (Libby 1996, Libby 2001). Macrophages also produce
 
tissue factor, the major procoagulant and trigger to thrombosis
 
found in plaques. Inflammatory 
mediators regulate tissue factor
 
expression by plaque macrophages, demonstrating an essential
 
link 
between arterial inflammation and thrombosis (Libby 2001). 
 
C-reactive protein (CRP) 
Structure and function 
CRP is a member of the phylogenetically ancient and highly conserved pentraxin family of proteins 
(Figure 1), which also includes serum amyloid P (SAP), a constituent of amyloid desposits (Volanakis 
2001). 
Human CRP is a calcium-dependent ligand binding protein that
 
binds with high affinity to 
phosphocholine residues, a constituent of many bacterial and fungal polysaccharides and of most 
biological cell membranes (Volanakis 2001). When human CRP is ligand bound, it activates the 
classical complement
 
pathway (Volanakis 2001). The secondary effects of CRP that follow ligand 
binding resemble
 
some of the key properties of antibodies, suggesting that under
 
various circumstances 
CRP may contribute to host defence against
 
infection (Volanakis 2001). CRP-mediated phagocytosis 
may be indirect, through activation of complement and complement receptors, or direct, through 
receptors for the Fc portion of immunoglobulin G (IgG; Fcgamma receptors) (Tornvall 2003) (Figure 
1). 
Phosphocholine is prevalent also in circulating plasma lipoproteins
 
that are intimately involved in the 
pathogenesis of atherosclerosis.
 
The specific binding of CRP to LDL and very-low-density
 
lipoproteins 
(VLDL) and to the membranes of damaged
 
cells has long been recognised (Pepys 1985, de Beer 1982, 
Rowe 1984), and more recently it
 
has been observed that CRP also binds to apoptotic cells in
 
a Ca
2+
-
dependent manner, enhancing their opsonization and phagocytosis
 
by macrophages (Gershov 2000). 
Plasma CRP is produced by
 
hepatocytes (Figure 2)  
 (Volanakis 2001), although other sites for CRP synthesis and possibly
 
secretion have been suggested 
(Hirschfield 2003). CRP may thus have a local role in particular microenvironments, such as the 
arterial wall, as well as
 
function via the systemic circulation. CRP
 
production is induced predominantly 
by the cytokine IL-6, but
 
IL-1 or TNF-α might also contribute (Mackiewicz 1991). The genes for both 
CRP and SAP are on chromosome 1 (Hirschfield 2003). Control of CRP expression
 
is principally at 
the level of transcription, and in vitro studies
 
in hepatocyte cell lines have identified some of the intra-
cellular
 
signalling pathways and also shown that secretion is more
 
efficient during an acute-phase 
response (Hirschfield 2003). Healthy subjects tend to have rather stable, unstimulated CRP 
concentrations that are significantly (35–40%) heritable (Hirschfield 2003).  
In healthy adult volunteer blood donors the median serum baseline CRP concentration was 0.8 mg/l 
(Shine 1981) but following an acute-phase stimulus,
 
values may increase by as much as 1000-fold, 
with de novo hepatic synthesis starting very rapidly. Concentrations
 
begin to rise at about 6 h, and 
peak around 48 h after
 
a single stimulus (Kushner 1978). In a healthy unselected population,
 
the 
median unstimulated CRP values are higher and tend to increase
 
with age. Females have higher 
circulating CRP concentrations (Hutchinson 2000). The plasma half-life of CRP is the same (about 19 
h) under all
 
conditions, and the sole determinant of the plasma or serum level
 
is the synthesis rate, 
which, in turn, reflects the
 
intensity of the pathological process(es) stimulating CRP production 
(Vigushin 1993). In vivo turnover studies of human CRP in man did not demonstrate
 
any detectable 
tissue deposition of CRP, even in inflamed or
 
infected foci (Vigushin 1993). 
Liver failure impairs CRP production, but no other intercurrent
 
pathology and very few drugs reduce 
CRP values, unless they
 
also affect the underlying acute-phase stimulus. Circulating CRP is thus a 
very useful non-specific biochemical marker of inflammation, a measurement of which contributes to 
screening
 
for organic disease and monitoring the response to treatment
 
of inflammation and infection 
(Hirschfield 2003).  
In order to use CRP as a cardiac risk marker in healthy subjects or in patients with CAD an accurate 
measurement of CRP within the conventional reference range (< 5 mg/l) is needed. The existing 
turbidimetric and nephelometric methods do not cover the required range and thus expensive, time-
consuming and labour-intensive enzyme immunoassays have been used for the clinical studies 
focusing on CAD risk. A new method based on microparticle enhanced turbidimetry or nephelometry, 
which attained the required limit of detection, while keeping the upper measuring limit comparable to 
the existing turbidimetric and nephelometric methods has been developed. The analytical detection 
limit of this type of method is approximately 0.2 mg/l (Eda 1998).  
Interestingly, evidence has recently accumulated that CRP might be a direct participant in the 
atherothrombotic
 
process capable of augmenting the innate inflammatory response by triggering 
expression of adhesion molecules and MCP-1, attenuating expression of eNOS,
 
inducing PAI-1, and 
having a direct
 
effect on arterial thrombosis (Lagrand 1999, Pasceri 2000, Fichtlscherer 2000). 
CRP and CAD 
Elevated plasma or serum CRP levels have been reported in patients with stable angina pectoris 
compared with healthy controls and it has been shown that CRP can predict long-term prognosis in 
these patients (Haverkate 1997, Zebrack 2002). The definition of elevated CRP in patients with CAD 
has been variable (range 3 to 25 mg/l) (Haverkate 1997, Heeschen 2000, Lindahl 2000, Morrow 1998, 
de Winter 1999) but generally higher than cut-off levels generated in primary prevention studies 
(range 0.6 to 8.5 mg/l) (Ridker 1997,1998 and 2000). 
In patients with unstable angina pectoris increased levels of plasma or serum CRP are associated with 
a worse outcome. Furthermore, it has been suggested that CRP contribute to the transition from a 
clinically stable to an unstable coronary atherosclerotic plaque (Haverkate 1997, Zebrack 2002, 
Lindahl et al 2000, Liuzzo 1999, James 2003,Berk 1990). 
The increase in circulating CRP following myocardial infarction is a typical
 
acute phase response to 
cell death and inflammation, mediated
 
by the action on the liver of the cytokine cascade, especially
 
IL-
6, triggered by the event. The magnitude
 
of CRP response reflects the extent of myocardial necrosis 
(Kushner at al 1978, de Beer 1982). Furthermore, peak CRP values at around 48 h after the onset,
 
predict outcome after myocardial infarction (Pietilä 1996, Ueda 1996, Anzai 1997). Importantly,
 
CRP 
is deposited within all acute myocardial infarcts (Kushner 1963, Lagrand 1997)
 
and compelling 
experimental evidence now suggests that the CRP
 
response not only reflects tissue damage in this 
context, but
 
may also contribute significantly to the severity of ischaemic
 
myocardial injury (Griselli 
1999). 
CRP and cardiovascular risk factors 
The relationship between CRP and CAD raises the question of how risk factors for CAD relate to this 
marker. Those with well-known risk factors for cardiac events, including the elderly, smokers, patients 
with hyperlipidemia, hypertension, obesity and diabetes mellitus may have a greater risk of CAD if 
their plasma CRP concentration is increased.  
Age 
The plasma CRP concentration increase with age. A survey of CRP levels in 5748 healthy subjects of 
all ages from the MONICA trial showed median levels double from the second to the sixth or seventh 
decade of life (Koenig 1999). Furthermore, the European Concerted Action on Thrombosis and 
Disabilities (ECAT) Angina pectoris Study showed that for patients 45–69 years old, CRP levels 
increased by 2% for each incremental year (Haverkate 1997).   
Smoking 
Plasma CRP concentrations are increased in smokers. An association between CRP and smoking was 
first described by Das in 1985, unfortunately CAD status was not recorded in that study. Many trials 
have documented that plasma or serum CRP concentrations are increased in smokers, including the 
ECAT (Haverkate 1997) and MONICA studies where CRP concentrations were twice as high in 
smokers as in non-smokers (Koenig 1999). Analysis of smoking in the Cardiovascular Health Study 
found that the plasma CRP value was strongly associated with smoking status (Tracy 1997). The 
MRFIT study of middle-aged men without CAD showed that an increased plasma CRP concentration 
was associated with an increased risk of mortality from CAD, with a relative risk of approximately 3. 
In this trial the association between CRP and CAD was true only for smokers (Kuller 1996). 
Furthermore, in the Helsinki Heart Study, smokers with a CRP in the highest quartile had a CAD risk 
of 9 compared with smokers with a low CRP that had a CAD risk of 1.5 (Roivainen 2000). However, 
the PHS showed that the risk of CRP was independent of smoking (Ridker 1997).  
Hyperlipidemia 
Several studies have shown that the risk of an increased plasma CRP concentration is independent of 
lipid levels both in healthy individuals and those with known CAD. In the Pysicians' Health Study 
(PHS) in individuals without a known history of CAD, the risk of a first myocardial infarction was 
more accurately predicted by baseline CRP than by plasma cholesterol or high density lipoprotein 
(HDL) cholesterol concentrations (Ridker 1997). The ECAT study found that the risk of coronary 
events in patients with stable angina pectoris with a high plasma cholesterol concentration was low if 
their CRP was low. A plasma CRP level of >3.6 mg/l increased the risk twofold for a coronary events 
compared with patients with CRP in the lowest quintile (Haverkate 1997). In patients with unstable 
angina patients and a high plasma cholesterol level, CRP predicted re-admission (Meier-Ewert 2001). 
Furthermore, although baseline values of plasma and HDL, cholesterol and CRP, all were associated 
with a first myocardial infarction, CRP and plasma cholesterol together increased the relative risk 
more than plasma cholesterol, plasma cholesterol/HDL ratio or CRP alone, by a factor of more than 2. 
Controlling for smoking habits, obesity, hypertension and diabetes mellitus did not affect these results 
(Ridker 1998). Similar results were found for women in the Women's Health Study (WHS), which 
showed that CRP and plasma cholesterol/HDL-C independently raised the risk of CAD (Ridker 2003). 
Women with high plasma CRP levels but normal LDL concentrations (<3.37 mmol/l) had a four times 
increased risk of a cardiovascular events compared with those with a low plasma CRP (Ridker 2000) 
suggesting that CRP can identify individuals at increased risk who otherwise would be missed if only 
lipid screening was used.  
Hypertension 
Hypertension is a risk factor for CAD that does not have a clearly understood pathophysiology. Some 
have speculated that the increased risk may be mediated through vessel wall inflammation, perhaps 
related to the renin–angiotensin system (Chae 2001). One small study found that the plasma CRP 
concentration in patients with essential hypertension was increased compared with healthy controls 
(Dodson 1984). It is unknown whether CRP values correlate with renin or angiotensin II levels in 
patients with essential hypertension, or whether these patients are more likely to develop 
cardiovascular events.  
Obesity 
The plasma CRP concentration is increased in patients with a high body mass index (BMI) as shown 
in several of the large studies (Haverkate 1997). The MONICA study showed that CRP was twice as 
high in those with an BMI > 30 compared with those with a normal BMI < 25 (Koenig 1999). In trials 
focusing on this issue, CRP was associated with measures of central obesity in women and men, a 
form of obesity that has previously been connected with a high CAD risk (Yudkin 1999. Hak 1999). 
The largest data base connecting CRP with obesity is the Third National Health and Nutrition 
Examination Survey of the US population performed between 1988 and 1994. Being obese conferred 
an increased odds ratio for having an increased CRP (2.13 for men and 6.21 for women) after 
controlling for other variables (Visser 1999). The association between an increased the plasma CRP 
concentration and obesity is prevalent in a wide range of individuals. Even in childhood, CRP is 
higher in those with an increased BMI (Cook 2000). Although the exact mechanism for the increased 
plasma CRP levels in obesity is not well-characterized, it is known that the liver synthesizes CRP in 
response to IL-6, and that IL-6 is released by adipose tissue (Mohamed-Ali 1997). 
Diabetes mellitus 
In a cross-sectional study by Ford (Ford Diabetes care 1999) the association between CRP,
 
and BMI 
and diabetes mellitus among 16.573 participants aged ≥ 20 years was examined. Serum CRP values 
were
 
lowest among individuals with a BMI < 18.5 without diabetes or impaired fasting glucose and 
increased with
 
increasing BMI categories and was highest among those
 
with newly or previously 
diagnosed diabetes mellitus after adjustment for age, sex,
 
race or ethnicity, education, and BMI (Ford 
1999). 
There is evidence indicating that a low-grade inflammation has as a potential role in the pathogenesis
 
of type 2 diabetes. Recently, data from the PHS (Pradhan 2001) and by Freeman and coworkers 
(Freeman 2002) identified elevated plasma levels of CRP as a predictor for the development of
 
diabetes mellitus in women and men independent
 
of risk factors such as BMI,
 
fasting triglycerides and 
blood glucose. Potential mechanisms for this association might be direct or indirect. For example, 
cytokines such as TNF-α may produce insulin resistance by influencing the function of the insulin 
receptor or by stimulating
 
adipocyte lipolysis. Alternatively, endothelial dysfunction
 
may link 
inflammation to insulin resistance. It is
 
also noteworthy that established mechanisms to decrease 
insulin
 
resistance, such as weight loss and thiazolidinediones have significant anti-inflammatory 
effects (Ridker 2003). Finally, an intracellular link between the inflammation cascade and insulin
 
signaling has been reported in a recent study showing that
 
salicylates prevents obesity and diet-induced 
insulin resistance
 
(Ridker 2003).
  
CRP, Infection and CAD 
Several studies have shown an association between antibodies against chronic infections such as 
cytomegalovirus (CMV), Chlamydia pneumoniae (CPN), Epstein-Barr virus (EBV), Helicobacter 
pylori (HPY), herpes simplex virus type 1 (HSV1) and 2 (HSV2) and coronary artery disease (CAD) 
(Blankenberg 2001, Danesh 2000, Ridker 2001, Hajjer 1987). Recent investigations have suggested 
that the CAD risk of infection is related to the pathogen burden i.e. the number of significant titres of 
antibodies against infectious pathogens, rather than to a specific pathogen (Zhu 2000, Espinola-Klein 
2002, Choussat 2000). It has been speculated that the increased risk for CAD associated with pathogen 
burden is mediated by inflammation (Zhu 2000, Georges 2003). However, the results of studies 
relating multiple antibodies against infectious pathogens to CAD have been inconsistent. First, Zhu 
and coworkers have shown, in women and men referred to coronary angiography, that CRP was 
associated with atheroslerosis and the aggregate number of antibodies against pathogens (Zhu 2000). 
More recently, De Backer and coworkers have shown that seropositivity against four infectious 
pathogens was not associated with CAD in a case-control study of middle-aged men (De Baker 2002). 
The results of studies concerning the impact of infectious burden on prognosis in CAD have also been 
contradictory. Two prospective studies of patients, a majority of men with coronary atherosclerosis 
documented by angiography, have shown that the risk of myocardial infarction or cardiovascular death 
was related to the pathogen burden independently of CRP (Espinola 2002, Zhu 2001). In contrast, 
Ridker and coworkers have shown that multiple antibody titres against infectious pathogens were not 
associated with the subsequent risk for CAD in a prospective nested case-control study in apparently 
healthy postmenopausal women (Ridker 1999). The importance of pathogen burden for the outcome 
after PCI has been investigated in one study only. Horne and coworkers have shown in patients with 
stable angina pectoris or ACS that pathogen burden was associated with clinical restenosis after PCI 
(Horne 2002). Because infection is a cause of inflammation it may contribute to persistently elevated 
plasma levels of CRP. Results from previous studies investigating the association between single or 
multiple antibodies against infectious pathogens and inflammation in patients with CAD have been 
somewhat contradictory. Pathogen burden has been shown to be associated with increased plasma 
CRP levels in studies by Zhu and coworkers (Zhu 2000) and Georges and coworkers (Georges 2003) 
whereas studies by De-Backer and coworkers (De Baker 2002) and Ridker and coworkers (Ridker 
1999) failed to show any association between seropositivity against multiple infectious pathogens and 
inflammatory markers. Furthermore, Choussat and coworkers showed in patients with ACS that acute 
phase proteins increased during the first 2 days of hospitilization but failed to demonstrate any 
association between the presence of seropositivity against multiple infectious pathogens and the 
inflammatory response (Choussat 2000).  
 
 Troponin  
The troponin complex is formed by three different forms of structural proteins (troponin C, I and T) 
located in the thin filament of the contractile apparatus of both skeletal and myocardial myocytes 
regulating the calcium dependent interaction between actin and myosin. Cardiac isoforms of troponin I 
and T are expressed solely in myocardial cells and released from the cytoplasma after disintegration of 
the cell membrane caused by myocardial necrosis. Accordingly, measurable plasma or serum levels of 
troponin I or T are highly specific for myocardial injury indicating even microscopic areas of necrosis 
irrespective of the cause (Collinson 2001). The initial rise of troponin concentration occurs 3 to 4 
hours after the ischemic injury with a persistent elevation up to two weeks after the event.  
Increased plasma troponin values have been shown to be more powerful prognostic indicators than 
CK-MB (Bahit 2002), and serial sampling enhances the likelihood of identifying myocyte necrosis 
among patients presenting at different stages of the myocardial infarction process (Newby 1998). 
While several manufactures have produced antibody-based assays for troponin I with different 
antigens, patent protection has meant that only Roche Diagnostics (Basel, Switzerland; formerly 
Boeheringer Mannheim of Mannheim, Germany) has produced a troponin T assay. Using the current 
generation of troponin T assay, the discrimination value for the detection of myocardial infarction is 
0.03 µg/l, which is higher than the 99th percentile of values of a healthy reference group. At 0.03 µg/l 
the coefficient of variation is ≤ 10% which meets the levels of precision specified in the European 
Society of Cardiology (ESC)/American College of Cardiology (ACC) definition (The Joint European 
Society of Cardiology/American College of Cardiology Committee. 2000).  
Apart from ACS, the most frequent causes of elevated circulating troponin concentrations are 
tachycardia, pulmonary emboli with right ventricular infarction (Perna 2002), and cardiac failure with 
myocardial necrosis caused by neurohumoral changes and elevated left ventricular end diastolic 
pressure. Other causes of increased troponin values include cardiac surgery, myocarditis, and renal 
failure in which the cause of myocyte necrosis yet has to be elucidated (Aviles 2002). 
Troponin  and clinical outcomes 
In both short (30-day) and long (up to 3 years) term follow-up studies, the magnitude of troponin 
elevation has correlated consistently with the risk of death or the composite risk of death or non-fatal 
myocardial infarction, irrespective of whether the patients had ST-elevation or non-ST elevation ACS 
(Klein 1997, Stubbs 1996, Ohman 1996. Antman 1996). In the global use of strategies to open 
occluded coronary arteries in acute coronary syndromes (GUSTO)-IIa troponin T substudy, the 
baseline troponin T value correlated with the risk of mortality at 30 days, and was the second most 
powerful prognostic predictor after electrocardiographic changes (Bahit 2002). The thromolysis in 
myocardial infarction (TIMI) group reported similar findings using a troponin I assay (Dade-Behring), 
with a linear increasing risk ratio for mortality at 42 days with increasing troponin values (Antman 
1996). 
Percutaneous coronary intervention (PCI) 
Historical perspective 
The introduction of PCI in 1977 by Andreas Gruntzig and two years later in Sweden at the Karolinska 
Hospital by Alfred Szamozi has had a dramatic impact on the practice of cardiology conceptually 
expanding the traditional role of the invasive cardiologist from diagnostician to "therapist" and 
providing an opportunity to learn more about coronary pathology and pathophysiology (Tornvall 
2002). In the first 50 patients who underwent PCI, the primary success rate was only 64% and 
emergency coronary bypass surgery (CABG) was required in 14% of the cases. Subsequently, as a 
result of greater operator experience and refinements in catheter and imaging technology, acute 
complication rates of PCI steadily decreased. However, acute thrombotic complications, restenoses 
and the need for repeat interventions occurring in up to 50% of cases, remained a severe limitation. 
This led to a search for more efficient catheter-based approaches such as directional atherectomy 
(DCA) (Baim 1993) and rotational atherectomy (Rihal 1998). An alternative strategy was placement 
of a permanent metallic intravascular scaffold or coronary stent. The first implantation of coronary 
stents in humans was performed in 1986 by Ulrich Sigwart in Switzerland. Because stent thrombosis 
occurred frequently during the first weeks after stent implantation, an intense search for the optimal 
antithrombotic therapy after stenting was instituted.  
Techniques of PCI 
Since coronary angioplasty encompassed the use of both balloons and other devices such as stents, the 
generic term of coronary angioplasty was changed from percutaneous transluminal coronary 
angioplasty (PTCA) to percutaneous coronary intervention (PCI). PCI results in lumen enlargement 
with dissection of the arterial intima and media, and stretching of the vessel circumference. Success of 
balloon angioplasty depends on both clinical and angiographic factors (Ellis 1988). Despite the 
improved initial success rate of balloon angioplasty, restenosis continued to occur in up to 40% of 
cases. Moreover, coronary lesions with bulky atherosclerotic plaques seemed to be less suitable for 
PCI. The DCA technique removes atheroma using a cutting and retrieval system. The initial 
encouraging results could not be confirmed in the randomized trials comparing DCA with balloon 
angioplasty (Topol 1993, Holmes 1995). DCA is currently used in certain bifurcation and ostial 
lesions, and for bulky eccentric plaques (Simonton 2000). Rotational atherectomy involves cutting and 
ablation of inelastic plaques by means of a high speed burr. It is usually used as debulking before stent 
placement in calcified lesions (Moussa 1997). Cutting balloon angioplasty is a strategy of atherotomy 
rather than atherectomy. It use balloons with microsurgical blades that incise atherosclerotic plaque 
resulting in a controlled  dissection. The main indications for this technique are restenosis including 
in-stent restenosis and ostial lesions (Ajani 2001).  
Coronary stents 
 Metallic stents are balloon-expandable or self-expandable scaffolds. Balloon-expandable stents are 
made of stainless steel whereas self-expanding stents are typically made of a memory metal such as 
self-expandable nitinol stents (Harnek 2002). Stents differ in length and diameter, flexibility, radio-
opacity, strut thickness, interunit geometry, size of strut windows and surface area coverage. They 
may either be passively or actively coated. An example of passive coating is covalentlybound heparin, 
used to prevent thrombosis in high-risk patients (Serruys 1998). An example of active coating is drug-
eluting stents coated with antiproliferative agents, which inhibit intima hyperplasia and reduce 
restenosis (Sousa 2001). Two randomized trials have been performed to compare stent implantation 
with balloon angioplasty: the STent REStenosis Study (STRESS) and the BEligum Netherlands 
STENT (BENSTENT) (Fischman 1994, Serruys 1994). Binary restenosis (defined as > 50% diameter 
stenosis) and a composite clinical end-point consisting of death, myocardial infarction, stroke, and the 
need for CABG or repeat PCI at 6 months was reduced in both trials. Long-term outcome of stent 
placement has been evaluated up to 3 years after implantation. Loss of initial gain of lumen diameter 
was limited to the first 6 months, after which minimal lumen diameter remained unchanged through 1 
year, and actually increased significantly by 3 years (Kimura 2002).  
Stent thrombosis 
Stent thrombosis is the most serious complication of stent implantation. It is associated
 
with 30-day 
mortality rates of 21% to 26% in recent series (Levine 2003). Stent thrombosis most frequently occurs 
in the first
 
days to weeks after stent implantation. Patients usually present
 
with severe chest pain and 
often have ST-segment elevation on electrocardiogram (ECG).
 
Randomized comparisons of 
antiplatelet and anticoagulation regimens were performed in the Intracoronary Stenting and 
Antithrombotic Regimen Study (ISARS) and Stent Antithrombotic Regimen Study (STARS) 
(Schomig 1996, Leon 1998) trials. There was a 7-fold reduction in the rate of stent thrombosis with 
aspirin and ticlopidine compared with anticoagulantion with warfarin. Major adverse cardiac events 
(MACE), including myocardial infarction and repeat target vessel revascularization (TVR), as well as 
bleeding were reduced (Schomig 1996, Leon 1998). More recently, clopidogrel has been shown to be 
as effective as ticlopidine in preventing stent thrombosis, with a lower incidence of skin rash and 
neutropenia and has therefore largely replaced ticlopidine (Bertrand 2000). Recent pooled analyses 
have confirmed the reduced stent thrombosis rate (0.9%–2.0%) (Cutlip 2001, Schulen 2001). 
The use of another group of adjunctive agents, intravenous glycoprotein IIb/IIIa inhibitors, have 
resulted in an absolute reduction of 1.5% to 6.5% in the 30-day risk of death, myocardial infarction, or 
urgent TVR, with some variability in the treatment effect among the agents tested (abciximab, 
eptifibatide and tirofiban) (Lincoff 2000). In the Evaluation of Platelet IIb/IIIa Inhibition for 
STENTing (EPISTENT), the primary end point of death, myocardial infarction, and TVR at 1 month 
was reduced from 10.8% to 5.3% by abciximab. This was mainly due to a reduction in large (CK >5 
times the upper limit of normal) non-Q–wave myocardial infarction (The EPISTENT investigators 
1998). In randomized trials, eptifibatide has also been shown to decrease ischemic complications in 
patients undergoing stenting (O´Shea 2001) while tirofiban was equal to abciximab in reducing 
MACE 6 months after the index coronary intervention (Moliterno 2002). 
Patients treated
 
with bare-metal stents should receive
 
4 weeks of clopidogrel, in addition to aspirin, to 
prevent stent
 
thrombosis. Because of a concern that late stent thrombosis may
 
develop in patients 
treated with drug-eluting stents, recent trials have extended clopidogrel treatment to 3-6 months after 
PCI (Levine 2003).  
Restenosis 
Restenosis is a process by which a PCI-treated arterial narrowing
 
reccurs over time. The restenosis 
process is believed to
 
occur because of a constrictive negative arterial remodeling (arterial 
"constriction")
 
and intimal hyperplasia (Levine 2003). Diabetes mellitus, unstable or severe angina 
pectoris at the time of PCI, are associated with an increased risk of restenosis. Furthermore, restenosis 
is associated with factors related to the procedure such as intervention in the left anterior descending 
artery or in a saphenous
 
vein graft, total length and diameter of the lesion treated, chronically
 
occluded 
arteries, previously treated lesions, and factors related
 
to technical aspects of the procedure itself, most 
notably minimum
 
luminal diameter immediately after the procedure (Levine 2003). The restenotic 
process occurs over the first one to 8 months
 
after PCI (Levine 2003). The presenting symptom for 
most patients with restenosis
 
is exertional angina (25% to 85%) while few patients (11% to 41%)
 
present with unstable angina pectoris. Presentation with acute myocardial infarction
 
is rare (1% to 6%) 
(Levine 2003). Stents reduces restenosis by providing a larger initial lumen and eliminate "arterial 
constriction" rather than reducing intimal hyperplasia (Levine 2003). The most promising therapy for 
prevention of restenosis is the use of drug-eluting stents. Several randomized trials are currently 
comparing the efficacy of drug-eluting stents with bare stents (Arjomand 2003). Initial reports showed 
a lack of angiographic restenosis at 1- and 2-year follow-up in the First-In-Man studies and 
RAndomized study with sirolimus-coated bx VELocity stent (RAVEL), respectively (Fajadet 2002, 
Sousa 2002). In the SIRolImUS eluting stent in de novo native coronary lesions (SIRIUS) trial, which 
included a more diverse patient group than the initial trials, angiographic restenosis occurred in 3% of 
patients treated with sirolimus-eluting stents compared with 35% of patients treated with bare stents 
(Moses 2002). A stent coated with paclitaxel has also been shown to be effective for decreasing 
neointimal proliferation within the stented segment and reducing the incidence of clinically significant 
in-stent or edge restenosis. Three randomised trials: the ASian Paclitaxel-Eluting Stent Clinical Trial 
(ASPECT) (Park Circulation 2001), the European evaLUation of pacliTaxel Eluting Stent (ELUTES) 
trial (Gershlick Circulation 2001) and TAXUS (Grube Circulation 2003) found that paclitaxel-coated 
stents significantly reduced angiographic restenosis at 6 months (0-4% vs. 10-27 % for bare stent). If 
these results are confirmed, the application of drug-eluting stents will be most beneficial in groups of 
patients at high risk for restenosis (ie, patients with small vessels, diabetes, chronic total occlusions, 
SVG lesions, and multivessel disease) (Arjomand 2003).  
 
 
Indications for PCI 
Indications for PCI have been suggested by the ACC/American Heart Association (AHA) Task Force 
(Smith 2001).  
Stable angina pectoris: 
Patients who are asymptomatic or have only mild symptoms are generally best treated with medical 
therapy unless one or more significant lesions, cause ischemia in a large area of viable myocardium 
confirmed by non-invasive testing and PCI can be performed with a high chance of success and a low 
likelihood of complications (Smith 2001). Patients with moderate or severe angina pectoris, 
particularly those who are refractory to antianginal therapy are suitable candidates for PCI, provided 
that the lesion, cause ischemia in a moderate to large area of viable myocardium as determined by 
non-invasive testing. Patients with recurrent symptoms while receiving antianginal therapy are 
candidates for PCI even if they have a moderate risk for an adverse outcome during revascularization 
(Smith 2001). 
Acute coronary syndrome 
In patients with unstable angina pectoris or non-Q-wave myocardial infarction, coronary 
revascularization might improve prognosis. The TIMI IIIB trial found no difference in death or 
myocardial infarction at 1 year in patients undergoing routine angiography and revascularization for 
recurrent ischemia. However, patients treated invasively experienced less angina and were 
rehospitalized less than those treated with a conservative approach (Anderson 1995). Patients assigned 
to early catheterrization and revascularization in the Veterans Affairs Non-Q-Wave Infarction 
Strategies In-Hospital (VANQWISH) trial experienced no reduction in the rate of death or the 
composite end-point of death or myocardial infarction at 1 year when compared with patients assigned 
to cardiac catheterization and intervention only for recurrent ischemia (Boden 1998). There are several 
other notable features of the VANQWISH trial. First, although the frequency of multivessel coronary 
artery disease was high (74% of patients in the invasive group had multivessel disease), only 44% of 
the patients assigned to invasive therapy actually underwent coronary revascularization, suggesting 
that the potential benefits of coronary revascularization were not completely realized. Second, 
although this study was performed before the widespread use of coronary stents and glycoprotein 
IIb/IIIa inhibitors, the clinical outcomes associated with PCI was quite favorable. Finally, coronary 
artery bypass graft surgery was performed in nearly 50% of the patients who underwent 
revascularization in the invasive arm. The 12% mortality rate in these patients exceeds the experience 
in this group of patients in other series (TIMI IIB 1994, FRISC II 1999, Cannon 2003) and is not fully 
explainable from the baseline clinical features. Thus, it is quite likely that the very high perioperative 
surgical mortality rate influenced the overall results of the trial. In contrast to the VANQWISH trial, 
the Fragmin during Instability in Coronary Artery
 
Disease (FRISC-II) trial demonstrated a significant 
reduction in death or myocardial infarction at 6 months in patients with non-ST-elevation ACS 
assigned to routine catheterization and revascularization versus those assigned to a conservative 
approach (The FRISC-II Investigators 1999). Furthermore, in Treat Angina with tirofiban and 
determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS) study, patients with 
unstable angina and myocardial
 
infarction without ST-segment elevation who were treated with
 
the 
glycoprotein IIb/IIIa inhibitor tirofiban, the use of an
 
early invasive strategy significantly reduced the 
incidence
 
of death or myocardial infarction at 6-month follow up (Cannon 2003). In the Randomized 
Intervention Treatment of Angina (RITA-3) trial (Fox 2002), patients with non-ST-elevation ACS 
were randomized to early intervention or a conservative strategy. At 4 months patients in the 
intervention group had a lower rate of the combined end-point of death, non-fatal myocardial 
infarction or refractory angina, compared with patients in the conservative group(10% vs 14%). This 
difference was mainly due to a reduction of refractory angina in the intervention group. Death or non-
fatal myocardial infarction were similar in both treatment groups at 1 year (7.6% vs 8.3%, 
respectively). Symptoms of angina improved and use of antianginal medications was significantly 
reduced with the interventional strategy (Fox 2002).  
Troponin T and PCI 
Myocardial necrosis, indicated by an elevation of a cardiac marker, occurs frequently in the absence of 
a clearly definable clinical
 
event after an otherwise successful PCI and is associated
 
with an adverse 
clinical outcome, including death (Davis 2003).
 
Detectable rises in CK-MB occurs following 5–30% of 
all PCI procedures, and have been associated with adverse outcomes
 
(death, myocardial infarction or 
TVR)
 
in both short (6-month) and long (up to 3 years) term follow-up studies (Califf 1998,Tardiff 
1999, Harrington 1995, Kong 1997). The relation between periprocedural CK-MB elevations and
 
late 
mortality is approximately linear, and myocardial necrosis
 
has a similar prognostic significance 
whether it is caused by
 
a "spontaneous" ischaemic event or by PCI (Akkerhuis 2002). 
A postprocedural rise in plasma troponin concentrations occurs in up
 
to 40% of PCI procedures 
(Cantor 2002, Davis 2003) and appears to have a prognostic significance
 
similar to that of elevated 
CK-MB values. In one study, 26%
 
of the patients with normal troponin values before PCI were found
 
to have concentrations above the upper limit of the reference
 
range after PCI (Cantor 2002). Of these 
patients the 90 day mortality
 
rate was 5% compared with 0% in patients without elevated troponin
 
I 
after PCI (risk ratio 4.3, 95% CI 1.4 to 13.5). Another recent study of 1872 PCI patients found
 
that 
32% developed elevated plasma troponin I concentrations after
 
the procedure. Elevated troponin I 
values, the
 
presence of diabetes mellitus, and age
 
were all independent predictors of 1 year mortality 
(Abizaid 2001). However, the association between increased periprocedural troponin levels and 
outcome for more than 1 year has not been investigated.  
Many studies have attempted to explore the aetiology of myocardial infarction during PCI. Clearly, 
patients who experience complications during PCI (side-branch occlusion, intimal dissection, coronary 
spasm and distal embolization) are more likely to have elevated troponin T after PCI (Davis 2003). 
Glycoprotein IIb/IIIa receptor
 
antagonists have been shown to reduce the incidence of periprocedural
 
myocardial infarction, and the reduction in long term mortality seen with abciximab
 
treatment supports 
the clinical importance of distal embolization (Chew 2001).
 
There is controversy as to whether the 
adverse long term prognosis
 
associated with periprocedural myocardial infarction is due to small areas 
of myocyte
 
necrosis, or whether periprocedural cardiac marker elevations
 
reflect a large atherosclerotic 
burden in the coronary arteries
 
and elsewhere (Tardiff 1999). The majority of deaths occurring after 
periprocedural
 
myocardial infarction has been reported as being sudden, which suggests an 
arrhythmiogenic
 
mechanism possibly related to multiple small areas of myocardial
 
necrosis (Brener 
2002). 
In a study by Akkerhuis and coworkers (2002) the relative increase in 6-month mortality was similar 
for CK-MB elevations after PCI and those occurring spontaneously in the setting of ACS. These data 
support the hypothesis that, regardless of aetiology, any myocyte necrosis has prognostic implications 
(Akkerhuis 2002). 
CRP and PCI 
Several studies have suggested that an elevated preprocedural (baseline) plasma or serum CRP level in 
patients undergoing percutanous coronary intervention (PCI) is associated with short-, intermediate- 
and long-term outcome (Table 1). Furthermore, the procedure itself has been shown to provoke an 
inflammatory reaction as shown by increased plasma CRP levels after PCI. However, the role of CRP 
response to PCI for prognosis has been investigated only in a few small studies (Table 2). To further 
explore the role of CRP and the factors that determine CRP in the setting of PCI, the following 
hypothesis and aims for this thesis was formulated.  
  
Hypothesis and Aims 
Hypothesis 
In the setting of PCI, CRP is an important prognostic factor that is influenced by pre- and peri- 
procedural factors. 
Aims 
 to investigate the impact of a baseline serum CRP determination, medication, and factors related to 
the procedure for the risk of myocardial infarction during PCI. 
 to investigate the influence of a thrombin-based femoral artery closure device on the serum CRP 
response to PCI. 
 to investigate the impact of pathogen burden on the CRP and IL-6 response to PCI. 
 to investigate the association between the CRP response to PCI and the long-term risk of death or 
non-fatal myocardial infarction and coronary revascularization during mean 2.6 years of follow-
up.  
 
 
  
Material and methods 
This thesis consist of 4 studies including patients recruited between Maj 1999 and June 2003. All 
included patients have undergone PCI at the Karolinska University Hospital in Sweden. Inclusion was 
performed during office hours, with breaks during weekends, Christmas and summer holidays. Details 
of inclusion and representativity are given in Figure 3 and Table 3.  
Study subjects  
Study I 
Between May 1999 and April 2001, 400 patients with stable or unstable angina pectoris and with 
normal serum troponin T levels, undergoing PCI at Karolinska University Hospital were prospectively 
recruited. Patients undergoing intervention in saphenous vein grafts (SVG) and patients treated with 
directional or rotational atherectomy were excluded in this study.  
 
Study II 
From a cohort of 685 patients admitted for PCI during office hours between January 2000 and October 
2002, 221 patients were retrospectively selected for this study. Patients with unstable angina pectoris, 
treatment with directional or rotational atherectomy, PCI performed through the radial artery, and 
patients with incomplete CRP and SAA data were excluded. Of the remaining, 100 patients were 
treated with a thrombin-based femoral artery closure device (Duett sealing device, Vascular Solutions, 
Minneapolis, Minnesota, USA) and 121 patients were treated with the FemoStop device (RADI 
Medical Systems, Uppsala, Sweden).  
 
Study III 
One hundred patients with stable angina pectoris scheduled for elective PCI at the Karolinska 
University Hospital were prospectively enrolled in the study between February 2001 and June 2003. 
Patients with acute infections, chronic inflammatory conditions and patients treated with drug-eluting 
stents or with a thrombin-based femoral artery closure device were excluded.  
 
Study IV 
A total of 891 consecutive patients undergoing PCI at the catheterization laboratory at the Karolinska 
University Hospital were prospectively investigated. Patients had stable or unstable angina pectoris 
with a normal serum troponin T (≤ 0.3 µg/l) before PCI.  
Follow-up 
Information about mortality and hospitalization was obtained from a registry kept by the Stockholm 
County Council. Data about myocardial infarction and coronary revascularization were obtained from 
hospital records. In cases where patients moved from Stockholm during the follow-up period (20 
patients) information was obtained by a telephone interview. 
Definitions 
Complications during PCI: side-branch occlusion, intimal dissection, coronary spasm and distal 
embolization.  
Myocardial infarction: combination of symptoms of myocardial infarction and elevated troponin I or 
T levels according to national guidelines. 
Periprocedural myocardial infarction: serum troponin elevation the day after PCI to a level > 0.05 
µg/l based on the recommendation for definition of myocardial infarction from the joint ESC/ACC 
committee (2000). 
Successful PCI: percentage of residual stenosis of < 50% in the worst of two orthogonal views. 
Laboratory procedures 
Blood sampling 
Study I-II and IV. Five ml of venous blood was collected immediately before PCI and at 6 a.m. the 
day after PCI (15-20 hours after PCI) for analysis of biochemical markers. 
Study III. Before and 6, 24, 48 and 72 hours after PCI, venous blood samples were collected in 
vacuum tubes and centrifuged immediately (plasma) or after 30 minutes (serum) at 2000 x g for 20 
minutes. Both plasma and serum samples were frozen at -80 ºC until analyses. 
Analyses 
C-reactive protein and Serum amyloid A. CRP and SAA concentrations were assayed in serum by a 
high sensitive method using particle-enhanced immunonephelometry with BN II analyzer reagent  
(Dade Behring, GmBH, Mamburg, Germany). In study III, CRP was measured in plasma by a high 
sensitive nephelometric method using particle-enhanced reagent (Dade Behring, Deerfield, IL, USA) 
in a Behring BN ProSpec analyzer (Dade Behring). The lower detection limit was 0.16 mg/L. 
Troponin T. In all studies troponin T levels were measured in serum except in study III where it was 
analysed in plasma. Measurements were performed with a Troponin T STAT, Cardiac T reagent 
(Roche Diagnostics, Mannheim, Germany) on a Elecsys 2010 immunoassay analyzer (Roche 
Diagnostics). The lower detection limit was 0.010 µg/l.  
Interleukin-6. Plasma IL-6 levels were determined using a high sensitive ELSA kit (HS600, R&D 
Systems, Minneapolis, MN, USA). The lower detection limit was 0.1 pg/ml. 
Serology. Antibodies of IgG-class (for Chlamydia pneumoniae (CPN) also antibodies of IgA-class) 
against different pathogens were examined by commercially available ELSA kits with the exception 
for cytomegalovirus where an inhouse ELISA was used. For CPN IgA EIA and IgG EIA 
(AniLabsystems Ltd. Oy, Helsiniki, Finland), for Ebstein-Barr virus (EBV) Anti-EBV VCA IgG 
ELISA (Biotest AG, Dreieich, Germany), for Helicobacter pylori (HPY) Pyloriset® EIA-G III (Orion 
Corporation Orion Diagnostica, Espoo, Finland). IgG-antibodies for HSV-1 and HSV-2 by 
HerpeSelect® 1 ELISA IgG and  HerpeSelect® 2 ELISA IgG (FOCUS Technologies, California, 
USA). Results were interpreted as positive or negative according to the manufactures´ instruction. All 
equivocal results were regarded as a negative results. 
Anticoagulantion therapy  
Patients undergoing PCI were in general treated with acetyl salicylic acid (ASA). In a few cases, 
patients had clopidogrel because of contraindications to ASA or warfarin when anticoagulation 
therapy was indicated for other reasons such as prevention of systemic or venous embolism e.g. in 
mechanical heart valve prosthesis, myocardial infarction, atrial fibrillation, deep venous thrombosis or 
pulmonary embolism. None of the patients in the studies received clopidogrel or ticlopedine in 
combination with ASA before PCI. Anticoagulation at the time of the procedure was administrated as 
unfractionated heparin (bolus 5000-15000 U aiming at an activating clotting time >300 s) or 
enoxaparin (0.5 mg/kg bodyweight) intravenously or intraarterialy at the start of, or enoxaparin 1 
mg/kg bodyweight subcutaneously within the last 6 hours before the procedure. Antithrombotic 
treatment with glycoprotein IIb/IIIa inhibitors were given as "bail out" if visible thrombus during the 
procedure. If stentimplantation, ticlopedine 250 mg were given twice or clopidogrel 75 mg once daily 
for 4 weeks in combination with ASA. All treatment before, during and after PCI was decided by the 
treating cardiologist. 
Femoral artery closure after PCI  
Duett sealing device is a non-mechanical femoral artery closure device. It contains a procoagulant 
mixture, comprised of 250 mg of bovine microfibrillar collagen (Avitene, Davol, Woburn, MA) and 
10000 units of bovine thrombin (Gentrac, Middleton, WI) reconstituted in 5 ml of phosphate buffered 
water for optimal viscosity, osmolarity and pH. This mixture is delivered after positioning  of a 
ballooncatheter. The balloon is inflated within the artery and retracted initially against the sheath and 
subsequently together with the sheath against the vessel wall. An attempt of aspiration through the 
sheath is made after 5 mm of retraction and thereafter the procoagulant mixture is injected through the 
sheath, with the intention of covering the external surface of the artery and sealing the track from the 
artery to the skin surface. After the end of the injection the balloon is deflated and removed through 
the sealed track. FemoStop device is a compression arch with a pneumatic dome that serve as a 
mechanical compression after inflation that permits removal of the sheath.  
 
Analysis of lesion morphology  
The ACC/AHA grading system (Table 4) (Ellis et al 1990) were used to classify the severity of 
lesions. Angiograms were evaluated by two interventional cardiologists. In case of disagreement, a 
third cardiologist was consulted. The cardiologists were blinded to the biochemical results. The lesion 
type of the most severe stenosis was evaluated in the statistical analysis in the case of intervention of 
more than one lesion.  
Statistics 
In study I a sample size of 400 patients made it possible to detect a difference in baseline CRP of 0.3 
mg/l between patients without or with myocardial infarction during the procedure with 80% power and 
p < 0.05. In study II, a sample size of 214 patients made it possible to detect a difference in CRP 
response to PCI of 0.3 mg/l between patients treated with the FemoStop device or Duett sealing device 
with 80% power and p < 0.05. In study IV, a sample size of 1000 patients was calculated to show a 4% 
absolute difference in death between patients with or without a periprocedural myocardial infarction 
with 80% statistical power and a one-sided significance level of < 0.05. During the study the primary 
end-point had to be modified to death or non-fatal myocardial infarction due to the low number of 
deaths. Continous data were expressed as mean ± SD when normally distributed and or as median 
(range) when skewed and group differences compared using non-parametric statistical methods with 
the exception of study 1 where continuos parameters were tested with Student´s unpaired t-test or with 
ANOVA with Scheffé as the post-hoc analysis after logarithmic transformation. Categorical data were 
expressed as frequencies (percentages) and differences between groups were tested by Chi-square test. 
In Study III, area under the curves (AUCs) were constructed for CRP, IL-6 and troponin T values 
obtained at 0, 24, 48 and 72 hours. AUCs were divided into tertiles and correlations between AUCs 
tertiles and pathogen burden were tested by Friedman ANOVA and Kendall´s concordance (multiple 
independent variables) otherwise Sperman rank correlation test was used to test associations between 
variables. In Study IV, CRP values were divided into tertiles while troponin T values were categorized 
into 3 categories; no myocardial infarction, small and large myocardial infarctions with a cut-off value 
of 0.14 μg/l obtained by using the median of the troponin T value the day after PCI of patients with 
myocardial infarction. Cox proportional hazard regression was performed to evaluate the effects of 
troponin T and CRP on outcome. The analysis also controlled for other important factors that could 
influence the results. The assumption of time independent hazard ratio was investigated by including 
the covariates as a function of time. A backward selection procedure was used for assessing which 
factors to include in the models. Multivariate analyses were performed by SAS 8.2 statistical software 
otherwise StatSoft, Inc. (2001). STATISTICA (data analysis software system), version 6, was used. A 
p value < 0.05 was considered to indicate statistical significance. 
 
 
 
 
 
 
  
Results and Discussion 
Study I 
This study was performed to evaluate the prognostic information of a preprocedural serum CRP 
determination to predict myocardial infarction during PCI.  
The study patients mean age was 63 years ± 10.7 and 28% were women. One third of the patients 
presented with unstable angina pectoris. The vast majority of patients were treated with ASA and 
cardioselective betablockers, whereas statins were used in more than two thirds of the patients prior to 
PCI. The majority of patients had one- or two-vessel disease with B-type stenoses according to the 
ACC/AHA classification. Approximately half of the interventions were in the left anterior descendent 
artery. Stents were used in 82% of the PCIs and complications during the procedure occurred in 9% of 
the procedures. Eighty three patients (21%) developed a myocardial infarction during the procedure 
with a median troponin T value 0.11 µg/l (0.06-5.0) after PCI. No association was found between 
preprocedural serum CRP levels and myocardial infarction during PCI (Figure 4). Furthermore, there 
were no differences between patients without or with myocardial infarction during PCI in terms of 
treatment with betablockers or statins. However, complexity of the stenosis and factors related to the 
procedure such as number of dilated vessels, stent use, complication during PCI and duration of the 
procedure were all associated with the risk of myocardial infarction during PCI. Patients with 
complications during the procedure had a longer procedure time and more complex lesions than those 
without complications. Abciximab use tended to be higher in patients with myocardial infarction 
during PCI. 
In multivariate logistic regression analysis, lesion type among preprocedural factors and stent 
implantation, complications during the procedure and duration of the procedure among periprocedural 
factors were associated with myocardial infarction during PCI. When all these independent pre- and 
periprocedural factors were included in the same model, stent implantation, complications during PCI 
and procedure length, but not lesion type, remained independently associated with myocardial 
infarction during the procedure (Table 5).  
The cardiac troponins I and T have emerged as highly sensitive and specific markers of myocardial 
cell injury (Adams 1993, Apple 1997). The ability of cardiac troponins to detect myocardial injury is 
considerably higher than CK-MB (Davis 2003). Percutaneous coronary interventions (PCI) are 
associated with a risk of myocardial infarction with a varying incidence depending on the method of 
detection and reference values (Davis 2003). Cardiac troponins have shown to provide important 
prognostic information, which allows risk stratification of patients presenting with ACS (Lindahl 
1996, Galvani 1997) and in patients undergoing PCI (Davis 2003, Nallamotu 2003). These data 
supports the consensus document recommendation from the ESC/ACC (The Joint European Society of 
Cardiology/American College of Cardiology Committee 2000) that emphasize that any increase in 
cardiac troponins results in an adverse prognosis. The incidence of myocardial infarction during PCI 
has been higher (40-60%) in previous reports using troponin I (Cantor 2002, Ricchiutti 2000) or 
troponin T (Abbas 1996, Karim 1995) than that observed in the present study (21%). Differences in 
baseline and procedural characteristics and inclusion of patients with elevated preprocedural troponin 
may be responsible for part of this discrepancy. Accordingly, the incidence of myocardial infarction 
during PCI in the study by Cantor and coworkers was 26% after exclusion of patients with increased 
or missing preprocedural troponin I values that is more in agreement with our findings. Furthermore, 
in a recent study by Nallamothu and coworkers (Nallamothu 2003) of 1157 patients with normal 
troponin I before PCI the incidence of periprocedural myocardial infarction was 29%. 
Several case-control studies have shown that patients with CAD have increased plasma or serum CRP 
levels compared with healthy controls. Furthermore, CRP can predict future CAD in healthy 
individuals and is associated with future cardiac events in patients with established CAD (Ridker 1997 
and 2000, James 2003). However, previously only one study has focused on the association between 
degree of inflammation, determined by plasma CRP, using a high sensitive method, before the 
procedure and the occurrence of myocardial infarction during PCI using troponin I as a (Saadeddin 
2002). Saadeddin and coworkers demonstrate marker of myocardial injury in 85 patients with stable 
angina pectoris undergoing elective PCI that an increased preprocedural serum CRP concentration was 
a independent determinant of myocardial infarction during the procedure, which is in disagreement 
with the results of the present study. The small patient sample of that study (85 vs 400 patients in our 
study), inclusion of patients with stable angina pectoris only and lack of estimation of risk ratios for 
increased CRP levels and other risk factors for myocardial infarction during PCI, makes it difficult to 
fully evaluate the results of the study by Saadeddin and coworkers. The possible explanation for our 
finding might be that elevated serum troponin T levels after the procedure reflects a thrombotic 
complication, due to downstream embolization with myocardial infarction as a consequence (Lindahl 
2001) while a low-grade inflammation, as determined by an elevated preprocedural CRP, might reflect 
the process of atherosclerosis and is therefore related to later adverse cardiac events. This speculation 
is supported by the study by Heeschen and coworkers (Heeschen 2000) that investigated the predictive 
values of serum CRP and troponin T in patients with unstable angina pectoris. They could not show 
that elevated plasma CRP levels increased the risk of cardiac events during the first 72 hours after 
admission to hospital. 
Statin therapy prior to PCI has been shown to improve short- and intermediate-term outcome (Chan 
2002, Bunch 2002). The results of the present study showed no association between medication with 
statins at the time of PCI and myocardial infarction during the procedure. One recent study has shown 
that statins attenuates the increased risk of major adverse cardiac events in patients with elevated CRP 
levels undergoing PCI with stentimplantation (Walter 2001). In this context, our results raise the 
possibility that the improvement of outcome seen with statins is mediated by decreasing the 
inflammatory response to PCI rather than decreasing the thrombotic activity responsible for 
myocardial infarction during the procedure. To better understand the mechanisms of how statins 
improve outcome after PCI randomized trials would be of great value. 
The role of prior medication with betablockers on short- and intermediate outcome in patients 
undergoing PCI is not clear. First, Sharma and coworkers (2002) showed that betablocker treatment at 
the time of PCI reduced CK-MB elevations after PCI and improved intermediate-term prognosis. 
However, in a larger study, Ellis and coworkers (Ellis 2001) found no relationship between 
betablocker use and subsequent rise in CK or CK-MB after PCI. The result of the current study 
confirm the finding of the latter study. An important limitation of the former two studies and our study 
is that betablocker treatment was not randomly assigned. Furthermore, 86% of the patients were 
treated with betablockers in the present study, hence it lacked sufficient statistical power to test the 
hypothesis of a possible positive effect of betablockers on the incidence of myocardial infarction 
during PCI. 
Complexity of the coronary artery stenosis has been associated with elevated plasma or serum 
troponin concentrations and adverse clinical outcome in unstable angina pectoris and after PCI 
(Bugiardini 1991, Kastrati 1999, Benemar 1999). In these studies, the ACC/AHA lesion classification 
scheme (Ellis 1990) was utilized for classification of the coronary lesion. However, the validity of  this 
scheme for evaluation of PCI outcome has been questioned (Tan 1995). In the present study, we found 
a univariate association between lesion complexity determined according to ACC/AHA lesion 
classification and elevated serum troponin T concentrations after PCI. However, this association failed 
to be significant in multivariate analysis.   
Factors related to the procedure (number of dilated vessels, stent implantation, duration of and 
complications during the procedure) were more reliable to predict the risk of myocardial infarction 
during the procedure. Complications during the procedure were associated with periprocedural 
myocardial infarction both in uni- and multivariate analysis. These results are in agreement with 
results of previous studies (La Vecchia 1996, Talasz 1992, Oh 1980, Bertinchant 1999, Johansen 
1998). However, complications did only explain part of the risk of myocardial infarction during the 
procedure. Other factors related to the procedure such as stent use and duration of the procedure were 
also associated with an increased risk of periprocedural myocardial infarction. 
Our result regarding a role of stent implantation in periprocedural myocardial infarction is in 
agreement with results of previous reports. Shyu and coworkers (Shyu 1998) showed in 120 
consecutive patients with stable or unstable angina pectoris undergoing PCI with or without stent 
implantation, that the frequency of increased plasma troponin T levels were higher than that of CK-
MB mass after the procedure (21% vs. 7%) and higher after stenting when compared with angioplasty 
alone (29% vs. 13%). In another study, elective PCI with stent implantation was associated with 
greater release of CK-MB mass than balloon angioplasty alone (Genser 1997). In contrast, a third 
report claims that the incidence of myocardial damage associated with stent implantation is low and 
comparable to that associated with balloon angioplasty and that measurement of both troponin T and 
CK-MB mass concentrations is essential in assessing minor myocardial damage (Ohnishi 1998). 
In summary, our results indicate that the risk of myocardial infarction during PCI cannot be predicted 
by determination of CRP before the procedure. Furthermore, the risk of periprocedural myocardial 
infarction is increased in patients with a long duration of the procedure and in patients treated with 
stentimplantation. These finding might provide useful information regarding the decision of the 
antithrombotic regime before, during and after the procedure, and the suitable grade of care needed 
after the procedure. 
Study II 
The present study was performed to evaluate whether the closing procedure of the femoral artery after 
PCI influences the degree of inflammation related to the procedure as measured by CRP and SAA. A 
thrombin-based device (Duett sealing device) was retrospectively compared with a mechanical 
compression device (FemoStop) in patients with stable angina pectoris. 
The mean age of the study patients was 66 years (± 10.2) and 23% were women. More than one third 
of the patients had treatment for hypertention and the majority were on ASA and statin therapy (91% 
and 76% respectively). Stents was used in 86% and complications during the procedure were reported 
in 7% of the interventions. Patients with femoral artery closure by the Duett sealing device were 
younger (64 vs 67 years), had a lower degree of significant CAD and less dilated vessels than those 
with femoral artery closure by the FemoStop device (1.12 ± 0.36 vs 1.25 ± 0.47). No differences 
existed in serum CRP and SAA values before and after PCI. Irrespective of femoral artery closure 
device serum CRP and SAA levels increased significantly after PCI. The increase was more 
pronounced in the Duett sealing device group compared with the FemoStop device group (Figure 5 
and 6). 
Various devices have been developed to replace standard manual or mechanical compression at the 
arterial puncture site to shorten bed rest following coronary angiography and PCI. Unfortunately the 
risk of peripheral vascular complications, such as hematoma and pseudoaneurysm formation, is 
slightly measured with the use of these devices compared with local compression at the puncture site 
(Koreny 2004). Several of these techniques deposit bovine microfibrillar collagen together with a 
high-dose of bovine thrombin directly above the femoral artery puncture site to obtain haemostasis. 
Thrombin has in addition to its role to promote hemostasis, proinflammatory activity through 
stimulation of release of proinflammatory cytokines (Johnson 1998). The biochemical mechanisms for 
such a response are still unclear. The results of this study support the notion that thrombin stimulates 
inflammation. 
The differences in baseline and procedural characteristics between the two groups are not likely to 
influence the results of the study. Patients in the FemoStop group were older which probably resulted 
in an underestimation of the differences in the inflammatory parameters because age has been 
associated with increased cytokine production upon stimulation (Roubenoff 1998). Recently, it has 
been shown that degree of CAD was not associated with CRP and therefore the differences regarding 
the degree of CAD between the two groups is not likely to have influenced our results (Veselka 2002). 
Finally, the number of dilated vessels were higher in the FemoStop group that something might have 
resulted in an increased of the inflammatory response to PCI, resulting in underestimation of the 
results. 
In summary, this study confirms that PCI triggers a systemic inflammatory response characterized by 
increased serum CRP and SAA levels after PCI (Azar 1997) and that this response was more 
pronounced when the arterial puncture is closed by a thrombin-based device than with a mechanical 
compression device. This effect of a thrombin-based device should be taken into consideration when 
deciding on the type of femoral artery closure device to be used after PCI. 
Study III 
The present study was performed to investigate the role of pathogen burden of infection in 
determining the magnitude of CRP and IL-6 response to PCI in patients with stable angina pectoris.  
The study patients had a mean age of 65 years (± 9.7) and 15% were women. More than 90% of the 
patients were treated with ASA or betablockers and 83% with statins. Seventy-four patients were 
dilated in one vessel and the remaining in two vessels. More than one third of the lesions was type 
B2/C and half of the patients were dilated in the LAD and 8% in SVG. Stent were used in 84 patients 
and only 2 patients had complications during PCI. Baseline plasma CRP increased from 1.2 mg/l 
(0.65-2.15) to a peak value at 48 hours of 6.45 mg/l (2.98-9.04) (Figure 7). Plasma IL-6 concentrations 
increased from 1.4 pg/ml (1.0-2.5) to a peak value at 24 hours of 6.1 pg/ml (3.9-9.9) (Figure 8).  
The pathogen burden, expressed as the number of seropositives distribution among the study group is 
shown in Figure 9. Pathogen burden was not associated with plasma CRP or IL-6 AUCs (Figure 10). 
This result did not differ when IgA antibodies were substituted for IgG antibodies against Chlamydia 
pneumoniae. No associations were found between individual pathogens and plasma CRP or IL-6 
AUCs.  
Patients with periprocedural myocardial infarction (21%) had a higher CRP AUC, however there was 
no correlation between plasma CRP and troponin T (r = 0.09) AUCs or IL-6 and troponin T AUCs (r = 
0.009). Patients treated with stentimplantation had higher plasma CRP and IL-6 AUCs compared with 
patients treated with balloon angioplasty alone (Figure 11 and 12). None of the other baseline or 
procedural factors were associated with CRP or IL-6 AUCs. 
Increased levels of systemic markers of inflammation, induced by PCI, may be a predictor of clinical 
outcome (Gaspardone 1998, Versaci 2000). The extent of such an inflammatory response has been 
suggested to be influenced by traditional cardiovascular risk factors, preprocedural treatment with 
ASA, statins and glycoprotein IIb/IIIa inhibitors or procedural factors. An association between 
seropositivity against bacterial or viral pathogens and CAD has been suggested (Blankenberg 2001, 
Danesh 2000, Ridker 2001, Hajjer 1987). Recently, the concept of pathogen burden has been 
proposed, i.e. exposure to multiple infectious agents might enhance the risk of CAD compared with a 
single exposure (Zhu 2000, Espinola-Klein 2002, Choussat 2000). Furthermore, it has been shown that 
CRP increase with the number of significant antibody titres and prediction of CAD by pathogen 
burden was limited to subjects with elevated CRP (Zhu 2000, Georges 2003). The present study is the 
first study to investigate the impact of pathogen burden on the magnitude of inflammatory response to 
PCI determined by plasma CRP and IL-6 levels. Our results could not confirm a role of pathogen 
burden in the inflammatory response to PCI. These results are in agreement with the result of a study 
by Choussat and coworkers (Choussat 2000). They showed, in patients with ACS, that acute phase 
proteins increased during the first 2 days of hospitilization but failed to demonstrate any association 
between the presence of seropositivity against multiple infectious pathogens and the inflammatory 
response. 
Several studies of patients treated with stent implantation, have suggested an enhanced CRP response 
to PCI (Aggarwal 2003, Almagor 2003, Gottsauner-Wolf 2000, Gaspardone 1998). However, in these 
studies the impact of stent implantation on the CRP response to the procedure has been difficult to 
evaluate since only patients treated with stentimplantation were included. In our study group, patients 
treated with stentimplantation had a higher plasma CRP and IL-6 increase after PCI compared with 
those treated with angioplasty alone. Recently, Liu and coworkers (2003) were not able to show any 
association between stentimplantation and CRP response to PCI. However, the patients in their study 
group had increased preprocedural CRP levels that might have obscured the results. Our results are 
more in agreement with the results of previous animal studies that have shown coronary artery stenting 
to cause a more severe arterial injury with a more intense inflammatory response within the vessel 
wall than balloon angioplasty alone (Hanke 1995, Kollum 1997, Hoffmann 1996, Hofma 1998). 
Another possibility for interpretation of our result is that the arterial overdistention by a high-pressure 
balloon inflation in the case of stentimplantation in comparison with angioplasty alone might be a 
possible explanation for the increased inflammatory response to PCI in patients treated with 
stentimplantation (Hoffmann 1999, Roger 1999). The lack of data regarding inflation pressure and 
time of inflation might therefore be considered a limitation of the present study. A third possible 
explanation might be that exposure of the metal of the stent in the vessel wall, being a "foreign body", 
trigger an increased inflammatory response. Irrespective of the aetiology, our finding suggests the 
interesting possibility that the mechanism behind the low incidence of restenosis with drug-eluting 
stents might predominantly be by reducing the local inflammation induced by PCI with 
stentimplantation. Furthermore, treatment with high dose prednisolone has also been shown to reduce 
restenosis in patients with increased plasma CRP levels undergoing stent implantation (Versaci 2002). 
Recently, a study by Bonz and coworkers (2003) aimed to investigate the effect of glycoprotein 
IIb/IIIa inhibitor on the inflammatory response to PCI. They stated that differences in the 
inflammatory response induced by the procedure are related to the presence or absence of troponin T 
release after the procedure. Their data are not consistent with our finding since we were not able to 
show any correlation between plasma CRP or IL-6 concentrations and plasma troponin T levels after 
PCI. However, after a careful review of their results, they were not able to demonstrate any significant 
difference in CRP levels between troponin-positive and troponin-negative patients. Our result add 
further information regarding the role of the inflammatory response in ACS as an independent risk 
factor not necessarily associated with myocardial injury.  
In summary, our results indicate that the CRP response to PCI cannot determined by neither infection 
with single or multiple pathogens nor a minor troponin T elevation after PCI. The inflammatory 
response to PCI was more pronounced in patients treated with stent implantation compared with 
angioplasty alone. These findings have implications for the mechanism of restenosis after 
stentimplantation and the cause of CRP and IL-6 increase seen in ACS.  
Study IV 
The present study was designed to determine whether the CRP response to PCI provide further 
information, in addition to a postprocedural increase in troponin T, to predict the risk for death or non-
fatal myocardial infarction and coronary revascularization in patients undergoing PCI. 
The study patients mean age was 63.6 years ±10.7 and they were predominantly men (73%). 
Seventeen of patients were current smokers and 14% had a previous diagnosis of diabetes mellitus. 
One third of the patients had presented with unstable angina pectoris. The majority of patients were 
treated with ASA and statins (92% and 77% respectively). Fifty-six percent of the patients had 1-
vessel disease, and 23% and 5% had 2- and 3-vessel disease, respectively. The vast majority of 
patients underwent PCI in one vessel (84.5%). Half of the PCIs were performed in LAD and stent 
were used in 85% of the PCIs. Complications during the procedure were reported in 7% of 
interventions. The CRP concentration was 1.82 (0.88-4.36) mg/l at baseline and 3.98 (1.98-8.84) mg/l 
after PCI, respectively. The troponin T concentration was 0.01 (0.01-0.01) µg/l before and 0.05 (0.01-
0.05) µg/l after PCI, respectively. There was no correlation between baseline CRP and troponin T after 
PCI (0.03, n.s.), while the CRP response to PCI were correlated to both baseline CRP (0.23, p < 
0.0001) and troponin T after PCI (0.09, p < 0.05). Twenty-one percent of the patients had a 
periprocedural myocardial infarction. Myocardial infarction during the procedure was associated with 
lesion characteristics (p < 0.001), number of dilated vessels (p < 0.001) and complications during PCI 
(p < 0.001). Of baseline and procedural characteristics; female gender, smoking, hypertension, 
diabetes mellitus, degree of diseased vessels, unstable angina pectoris, medication with ASA (inverse 
relation) and interventions in LAD or SVG were associated with baseline CRP. Female gender, 
complication during PCI and interventions in SVG were associated with THE CRP response to PCI. 
Baseline CRP levels was not associated with periprocedural myocardial infarction (1.76 mg/l [0.88-
4.44] vs 1.83 mg/l [0.91-4.35]) , while the CRP response to PCI was higher in in patients with 
periprocedural myocardial infarction (1.85 mg/l [0.46-5.62] vs 1.34 mg/l [0.35-3.29], p < 0.01).  
 A primary end-points occurred in 76 patients (total 8.5%, 4.6% death and 3.9% non-fatal myocardial 
infarction), respectively and a secondary end-point occurred in 130 patients (total 15.0%, 12.0% PCI 
and 3.0% coronary artery by-pass graft operation), respectively at the end of follow-up period. Age, 
female gender, diabetes mellitus, unstable angina pectoris, number of diseased coronary arteries, 
treatment with glycoprotein IIb/IIIa inhibitor and ASA (inverse relation) were associated with death or 
non-fatal myocardial infarction. Unstable angina pectoris and stent use (inverse relation) were the only 
baseline or procedural parameters associated with coronary revascularization. An Increased 
preprocedural CRP serum concentration was associated with death or non-fatal myocardial infarction 
in univariate but not in multivariate analysis. The CRP response to PCI and periprocedural myocardial 
infarction were associated with death or non-fatal myocardial infarction in both uni- and multivariate 
analysis (Table 6, Figure 13 and 14). Revascularization only associated with the CRP response to PCI 
in univariate and after adjustment for age, stent, baseline CRP and troponin T atfter PCI, in 
multivariate analysis (Table 7 and Figure 15). 
Preprocedural plasma or serum CRP levels have previously been shown to predict short- and 
intermediate-term outcome in patients undergoing balloon angioplasty with stent implantation (Table 
1 introduction section). The association between baseline CRP and long-term outcome has been 
elucidated only in a few studies (Lendelink 2003, de Winter 2002 and 2003). In the present study the 
serum baseline CRP concentration was associated with the risk of mortality and morbidity up to more 
than 2 years after PCI in univariate analysis. Differences in patients characteristics between previous 
studies and ours e.g. inclusion of patients with elevated preprocedural markers of myocardial injury or 
investigating patients with stent implantation or stable angina pectoris only in these studies, make our 
study result more reliable in assessing the role of preprocedural CRP for long-term prognosis.  
The result regarding the association between increased preprocedural CRP and the need for coronary 
revascularization, has been inconsistent. In agreement with previous reports (Dibra 2003, Horne 2002, 
Lenderlink 2003, Zhou 1999), our study showed that a baseline CRP determination could not predict 
the risk for coronary revascularization. However, it is not clear why some earlier studies (Buffon 1999, 
Gaspardone 1998, Heeschen 2000, Versaci 2000) reported an association between baseline CRP and 
restenosis.  
  
General discussion 
In the studies included in this thesis the prognostic information of serum levels of CRP before and 
CRP response to PCI was investigated. Furthermore, the studies investigated if pre- and periprocedural 
factors determine the CRP response to PCI. The results show that serum CRP levels before the 
procedure were not associated with periprocedural myocardial infarction. Furthermore, the CRP 
response to PCI was an independent predictor of death or myocardial infarction and revascularization 
up to more than 2 years after PCI. The CRP response to PCI was more pronounced in patients treated 
with stent implantation or femoral artery closure using a thrombin-based device whereas the pathogen 
burden before the procedure was not associated with the CRP response to PCI. 
Myocardial infarction during PCI occurs frequently in the absence of a clearly definable clinical
 
event 
after an otherwise successful PCI, and is associated
 
with an adverse clinical outcome, including death 
(Califf 1998, Ohman 1997, Tardiff 99). Thrombotic complications have suggested to be the major 
cause of the periprocedural myocardial infarction. In study I, an increased serum CRP level before PCI 
was not associated with myocardial infarction during the procedure. In contrast, Danenberg and 
coworkers (2003) demonstrated that arterial injury in mice transgenic for human CRP results in a 
higher rate of thrombotic occlusions compared with wild-type mice, which do not produce CRP. The 
authors concluded that CRP has a possible causal role for an increased rate of arterial thrombosis after 
controlled vascular injury. Our results could not support that this occurs in humans, PCI being a good 
model for vascular injury. However, an adverse impact of an increased preprocedural serum or plasma 
CRP concentration might be evident later after PCI. Periprocedural factors such as duration of the 
procedure, stent implantation and complications during the procedure seem to be more relevant than 
the preprocedural CRP for myocardial infarction during PCI. Distal protection devices during PCI has 
demonstrated the presence of embolic debris supporting the suggestion that distal embolisation during 
PCI is the most common pathophysiology behind myocardial infarction during PCI (Grube 2001). The 
utilisation of such devices and glycoprotein IIb/IIIa inhibitor might reduce the incidence of myocardial 
infarction during PCI. 
PCI has consistently been shown to provoke an inflammatory reaction as shown by increased 
inflammatory markers after PCI. The results from study II showed that a femoral artery closure device 
containing bovine thrombin might enhance the inflammatory reaction induced by PCI. A 
proinflammatory activity of thrombin might be linked to its ability to costimulate the release of several 
inflammatory cytokines, including MCP, IL-1, IL-6, IL-8, TNF-α (Johnson 1998). Whether the local 
inflammatory response induced by thrombin in the thrombin-based device contribute to augment 
systemic inflammation and accelerate atherogenesis is unclear. However, it has been shown that local 
inflammation in the synovial tissue (synovitis) in rheumatoid arthritis can release cytokines into the 
systemic circulation. These circulating cytokines alter function of distant tissues including adipose, 
skeletal muscle, liver, and vascular endothelium to generate a spectrum of proatherogenic changes that 
include insulin resistance, dyslipidemia and endothelial dysfunction (Sattar 2003). The findings of our 
study needs to be verified in a prospective randomized trial with the focus on the long-term prognostic 
impact of an increased inflammatory response by a thrombin-based femoral artery closure device. 
It has been suggested that there is an association between previous infection with cytomegalovirus 
(CMV), Chlamydia pneumoniae (CPN), Epstein-Barr virus (EBV), Helicobacter pylori (HPY), herpes 
simplex virus type 1 (HSV1) and 2 (HSV2) and CAD (Frishman 2002). The risk posed by infection 
might be associated to the aggregate number of pathogens (pathogen burden) rather than by one 
specific pathogen. Pathogen burden might contribute to CAD through an increased inflammatory 
response (Zhu 2000, Georges 2003). Much to our surprise, in study III we could not demonstrate any 
association between pathogen burden and the CRP response to PCI. Further investigations of factors 
that determine the inflammatory response to PCI are needed since animal and human studies suggest 
that host factors modulate the magnitude and extent of inflammatory response (Liao 1993, de Maat 
1996, Pankow 2001). There is evidence of a substantial heritability (35–40%) of plasma CRP levels 
(Pankow 2001). Further efforts to identify gene loci affecting these traits are warranted. The role of 
genetic variation of inflammatory markers with PCI as a stimuli should be evaluated. 
Over a 2-year follow-up, the risks of death or non-fatal myocardial infarction and revscularization 
were significantly higher in patients with an increased CRP response to PCI. In adjusted statistical 
analyses, the CRP response to PCI was a strong independent predictor of long-term mortality and 
morbidity in addition to a minimal troponin elevation after the procedure. The mechanisms behind the 
association between the CRP response to PCI and death or non-fatal myocardial infarction might be 
different than that between the CRP response to PCI and revascularization. The exact mechanisms 
behind these association are unclear. However, several experimental studies have revealed a broad 
range of potentially atherogenic properties of CRP (Yeh 2003). The results of study IV raises the 
question of whether the CAD risk associated with the CRP response to PCI is modifiable. Researchers 
have investigated the effects of interventions and medications already in use in CAD prevention 
including treatments that have anti-inflammatory effects, such as dietary changes, weight loss, 
exercise, ASA and statins (Lind 2003). Furthermore, the promising effect of drug-eluting stents to 
prevent restenosis (Arjomand 2003) might be mediated by attenuating the inflammatory response to 
PCI. 
Future directions 
Despite our findings regarding the strong independent role of CRP response to PCI on long-term 
prognosis, several issues have to be evaluated before measurement of CRP can be used for risk 
prediction in the setting of PCI in clinical practice. First, it has to be established if CRP is merely a 
marker for CAD or if it is actually directly involved in the pathogenic process of CAD and restenosis. 
Second, in an ideal prospective study a large number of inflammatory markers should be measured in 
order to evaluate if one of these markers are superior to others and whether the same inflammatory 
marker could be used to predict risk in both acute and chronic phases of CAD. Third, the effects of 
established therapies, directed towards conventional cardiovascular risk factors, on CRP should be 
further evaluated in randomized outcome trials. Fourth, in the future specific drugs that block the 
increase in CRP in CAD need to be developed and tested in outcome trials. This would be the ultimate 
test to evaluate if CRP is involved in the pathogenesis of CAD and restenosis, and thus CRP could 
serve as a surrogate biomarker for this process. 
As early as 1997 Azar and coworkers showed that PCI by itself can induce an inflammatory response 
as expressed by increased serum CRP levels after the procedure (Azar 1997). Only two small studies 
have investigated the role of the CRP response to PCI for prognosis. In a study group consisting of 81 
patients with stable agina pectoris and one vessel coronary artery disease undergoing PCI with stent 
implantation, Gaspardone and coworkers (1998) showed that persistent increased CRP levels at 72 
hours after PCI were associated with a combined end-point of cardiac death, non-fatal myocardial 
infarction and recurrence of angina pectoris. In contrary to this finding, Liu and coworkers (2003) 
showed that elevated plasma concentrations of secretory type II phospholipase A2 (sPLA2) after PCI, 
which is involved in the production of various pro-inflammatory lipids, but not the CRP response to 
PCI, were associated with a combined end-point consisting of coronary death, non-fatal myocardial 
infarction and recurrence of angina pectoris in 247 patients. This discrepancy was found despite a high 
correlation between CRP and sPLA2. The elevated baseline CRP levels before PCI in that study might 
have obscured the increase in CRP stimulated by the procedure. In our large cohort of PCI patients we 
were able to study separate endpoints; death or non-fatal myocardial infarction and risk of coronary 
revascularization. Furthermore, our study is the first to investigate the combined prognostic value of 
baseline CRP, CRP response to PCI and periprocedural myocardial infarction determined by troponin 
T in a large consecutive group of patients without increased preprocedural troponin T concentrations 
undergoing PCI. The results clearly showed that the CRP response to PCI, in addition to that of a 
baseline CRP and periprocedural myocardial injury, had a strong prognostic value to predict the risk 
for death or non-fatal myocardial infarction and coronary revascularization. 
The association between increased periprocedural troponin levels and outcome for more than 1 year 
has not been investigated. Furthermore, the cut-off of troponin concentration to identify PCI patients at 
risk for adverse events is not clear. In a recent meta-analysis of 2605 patients who were followed up 
more than one year after PCI an increased troponin level after PCI using the recomended cut-off 
values according to ESC/ACC guidelines (The Joint European Society of Cardiology/American 
College of Cardiology Committee 2000), did not correlate with an increased incidence of a composite 
end-point consisting of cardiac death, non-fatal myocardial infarction and the need of revascularization 
(Wu 2002). It was difficult to interpretate the results of the majority of the reports included in this 
meta-analysis since the only abstract were published (Wu 2002). In the present study, also a minor 
periprocedural myocardial infarction (serum troponin T > 0.14 µg/l) was associated with an 
independent risk for death or non-fatal myocardial infarction. Of note an increased troponin T 
concentration of > 0.14 µg/l the day after PCI in combination with a CRP response to PCI in the 
highest tertile was associated with a more than 5 times increase in risk of death or non-fatal 
myocardial infarction up to more than 2 years after PCI.  
Our results might have therapeutic implications. It can be speculated if it is possible to  decrease the 
risk of future coronary events by lowering the CRP response to PCI. Observational studies have 
suggested that statin therapy decrease the risk for major adverse cardiac events in patients with 
elevated plasma CRP levels undergoing PCI with stent implantation (Chan 2002, Walter 2001). 
Contrary to this finding, our results showed no associations between baseline CRP or CRP response to 
PCI and prior medication with statins. Furthermore, treatment with statins was not associated with 
outcome.  Controversy still exists regarding the benefit of ASA therapy in decreasing CRP levels and 
thus improving outcome (Feldman 2001, Feng 2000, Ikonomidis 1999). In the present non-
randomized study medication with ASA was associated with a lower baseline CRP and with a 
decreased incidence of death or non-fatal myocardial infarction during follow-up. Furthermore, oral 
therapy with high dose prednisolone in patients with increased plasma CRP levels 72 hours after 
coronary artery stent implantation results in a reduction of restenosis (Versaci 2002). In order to better 
evaluate of the effects of various anti-inflammatory therapies on CRP levels and the associations with 
outcome in patients with CAD, large randomized studies are needed particularly in the setting of PCI. 
In summary, an elevated serum CRP concentration in response to PCI is a strong independent 
predictor of death or non-fatal myocardial infarction and coronary revascularization independent on 
myocardial injury during the procedure. The result emphasize the role of CRP in CAD, and the need to 
develop treatments that block the increase in CRP in CAD. 
 
 
 
 
  
CONCLUSIONS 
Periprocedural factors such as duration of the procedure, stent implantation and complications during 
the procedure, whereas not the preprocedural CRP were associated with the risk of myocardial 
infarction during PCI. However, an elevated serum CRP concentration in response to PCI is a strong 
independent predictor of death or non-fatal myocardial infarction and coronary revascularization 
independent on myocardial injury during the procedure. Furthermore, the CRP response to PCI was 
more pronounced in patients treated with stent implantation or femoral artery closure using a 
thrombin-based device whereas the pathogen burden before the procedure was not associated with the 
CRP response to PCI. 
Taken together, the results emphasize the role of CRP in CAD, and the need to develop treatments that 
block the increase in CRP in CAD. 
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